Sucampo Pharmaceuticals Inc (NASDAQ:SCMP) (TREND ANALYSIS) shares were traded with no significant volume change. The stock closed last trading session at $21.48, up by 9.93%, with a volume of 1,111,508 shares against an average volume for the last 3 months of 1,081,230.
Stock Performance: Click here for a free comprehensive Trend Analysis Report
Sucampo Pharmaceuticals Inc (NASDAQ:SCMP) stock is currently trading 27.6% below its 52-week-high, 234.06% above its 52-week-low. The 1-year stock price history is in the range of $6.43 – $29.67. Sucampo Pharmaceuticals Inc (SCMP) has a price to earnings ratio of 36.59 versus Healthcare sector average of 44.17. SCMP stock price has outperformed the Nasdaq by 49.5%. The Medical Drugs company is currently valued at $0.96 billion and its share price closed the last trading session at $21.48. The stock has a 50-day moving average of $24.72 and a 200-day moving average of $19.89.
Sucampo Pharmaceuticals Inc (SCMP) current short interest stands at 4.18 million shares. It has increased by 14% from the same period of last month. Around 20% of the company’s shares, which are float, are short sold. With a 10-days average volume of 1.27 million shares, the number of days required to cover the short positions stand at 3.3 days.
The company is expected to announce next quarter earnings on November 05, at consensus estimate of $0.19. Sucampo Pharmaceuticals Inc (SCMP) reported last quarter earnings on August 05. The Medical Drugs company announced earnings per share of $0.21 against a consensus Street estimate of $0, beating the average estimate by $0.21. This corresponds to a decrease of $0.04 compared to the same quarter of the previous fiscal year.
Is this a Buying Opportunity? Click here for a free Trend Analysis Report
There are currently five analysts that cover Sucampo Pharmaceuticals Inc stock. Of those five, three have a Buy rating, two have a Hold rating. On a consensus basis this yields to an Overweight rating. The consensus target price stands at $29.
A recent analyst activity consisted of H.C. Wainwright reiterating their Buy stance on August 27. H.C. Wainwright increased their price target on SCMP from $31 to $36. This corresponds to a 67.6% upside from the last closing price. On the date of report, the stock closed at $27.92.
Another research firm was Cantor Fitzgerald who downgraded their Buy rating to Hold on May 7. Cantor Fitzgerald fixed their price target at $18. This translates to a 16.2% downside from the last closing price. On the date of report, the stock closed at $14.5.
Sucampo Pharmaceuticals, Inc. researches and develops drugs based on protones, which are derived from functional fatty acids. The Company produces a prescription drug for the treatment of chronic idiopathic constipation.